CTNM
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ · Healthcare · Biotechnology · US
$16.70
−4.95%Next report
Analyst consensus
- Next report date
- Oct 29, 2026
- EPS estimate
- -$0.45
- Revenue estimate
- $5.7M
Latest reported
- Last report date
- Jul 30, 2026
- EPS actual
- -$0.40
- EPS estimate
- -$0.45
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +9.1%
- Revenue beats (12Q)
- —
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 29, 2026